Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Here we show that proinflammatory T cells inhibit the ability of exogenously added bone marrow mesenchymal stem cells (BMMSCs) to mediate bone repair. This inhibition is due to interferon g (IFN-g)-induced downregulation of the runt-related transcription factor 2 (Runx-2) pathway and enhancement of tumor necrosis factor a (TNF-a) signaling in the stem cells. We also found that, through inhibition of nuclear factor kB (NF-kB), TNF-a converts the signaling of the IFN-g-activated, nonapoptotic form of TNF receptor superfamily member 6 (Fas) in BMMSCs to a caspase 3-and caspase 8-associated proapoptotic cascade, resulting in the apoptosis of these cells. Conversely, reduction of IFN-g and TNF-a concentrations by systemic infusion of Foxp3 + regulatory T cells, or by local administration of aspirin, markedly improved BMMSC-based bone regeneration and calvarial defect repair in C57BL/6 mice. These data collectively show a previously unrecognized role of recipient T cells in BMMSCbased tissue engineering. 
BMMSCs are nonhematopoietic multipotent stem cells capable of differentiating into both mesenchymal and nonmesenchymal cell types, including osteoblasts, adipocytes and chondrocytes [1] [2] [3] [4] [5] . To date, a variety of preclinical and clinical studies have shown that exogenously added BMMSCs can give rise to the generation of new bone and bone-associated tissues to replace damaged and diseased tissues by assisting the regenerative capacities of endogenous cells in the defect [6] [7] [8] [9] . However, the specific function of the recipient cells, especially immune cells, in BMMSC-based tissue regeneration remains unclear 9 .
Previous studies have shown that BMMSCs reduce inflammatory cytokines through interplay with several subsets of immune cells 10 . The immunoregulatory capacity of BMMSCs makes them of great interest for clinical applications in treating a variety of human diseases, such as acute graft-versus-host disease and systemic lupus erythematosus, as well as in promoting engraftment [11] [12] [13] . Conversely, interleukin-2 (IL-2)-activated natural killer (NK) cells and T cells activated by CD3 and CD28 can induce BMMSC apoptosis through the Fas-Fas ligand (FasL) pathway 14, 15 . Thus, the crosstalk between implanted donor BMMSCs and recipient immune cells may have a key role in determining the success of BMMSC-mediated tissue regeneration. We show here that recipient immune cells, specifically T cells, govern BMMSC-based tissue regeneration.
RESULTS

Recipient T cells modulate BMMSC-mediated bone regeneration
BMMSC-mediated bone regeneration is partially controlled by the recipient local microenvironment in which immune cells and cytokines may affect the BMMSCs. Using an established in vivo BMMSC implantation system in which 4 × 10 6 BMMSCs and carrier hydroxyapatite tricalcium phosphate (HA-TCP) particles were subcutaneously implanted into C57BL/6 or nude mice (Fig. 1a) , we found that autologous BMMSCs did not generate bone in C57BL/6 mice ( Supplementary Fig. 1 ). In contrast, when we implanted BMMSCs into T cell-deficient nude mice, they formed bone and bone-associated hematopoietic marrows (Fig. 1b) . To examine whether recipient T cells affected BMMSC-mediated bone formation, we infused 1 × 10 6 pan T cells, which were isolated using a pan-T cell isolation kit and were therefore not preselected for any particular subpopulation of T cells, into nude mice 2 d before subcutaneous BMMSC implantation and found that subsequent BMMSC-mediated bone formation was completely blocked (Fig. 1b) . These data indicate that recipient T cells may have a crucial role in inhibiting BMMSC-mediated bone formation.
Next we examined whether specific subsets of T cells blocked BMMSC-based bone regeneration. We found that intravenous infusion of 1 × 10 6 CD8 + T cells partially blocked BMMSCmediated bone formation, and CD4 + or CD4 + CD25 − T cell infusion totally blocked BMMSC-mediated bone formation in nude mice (Fig. 1b,c) . However, administration of CD4 + CD25 + Foxp3 + regulatory T cells (T reg cells) had no inhibitive effect on BMMSCmediated bone formation but rather improved the formation of bone marrow elements (Fig. 1b,c) . After systemic infusion of CD4 + T cells prelabeled with PKH26 red fluorescent dye into nude mice, we detected a transient elevation of CD4 + T cell concentrations in bone marrow, peripheral blood and spleen within 7 d after infusion (Supplementary Fig. 2a-c) and found the infused CD4 + T cells at areas around the BMMSC implants ( Supplementary  Fig. 2d ). Furthermore, we found that BMMSC-mediated bone formation started 14 d after implantation and that a substantial amount of bone was formed at 21 d after implantation ( Supplementary   Fig. 3 ). Inhibition of bone formation by CD4 + T cell infusion may be due to the cytokines produced by the CD4 + cells.
To explore the mechanisms of T cell-regulated BMMSC-based bone formation, we assessed the concentrations of a variety of cytokines, including IFN-γ, TNF-α, IL-4, IL-6 and IL-17A, in the BMMSC implants (Fig. 1d) . Notably, the concentrations of IFN-γ and TNF-α in the BMMSC implants were significantly (P < 0.05) elevated at 7-14 d after BMMSC implantation in C57BL/6 mice and nude mice that received pan T cells or CD4 + CD25 − T cells (Fig. 1d) . The high concentrations of IFN-γ and TNF-α were correlated with lack of new bone formation (Fig. 1b,c) . Conversely, the concentrations of the cytokines described above were not altered in the BMMSC implants derived from nude mice or nude mice infused with T reg cells (Fig. 1d) ; these implants showed a substantial amount of new bone formation (Fig. 1b,c) . Thus, the increase in the concentrations of IFN-γ and TNF-α is negatively correlated with BMMSC-mediated bone formation.
To further assess the role of cytokines in BMMSC-mediated bone formation, we co-implanted 200 ng of IFN-γ, TNF-α, IL-4, IL-6 or IL-17A subcutaneously with BMMSCs into nude mice (Fig. 1e,f ) . Treatment with IFN-γ or TNF-α significantly reduced BMMSC-mediated bone formation in nude mice (Fig. 1e,f) . However, treatment with IL-4 or IL-6 slightly inhibited BMMSC-mediated bone formation (Fig. 1e,f) , and IL-17A treatment had no inhibitory effect on BMMSC-mediated bone formation when compared to the untreated mice (Fig. 1e,f) . Neutrophils and lymphocytes were present at the BMMSC implants at 2 d and 4-7 d after implantation, respectively, and became almost undetectable at 14 d after implantation in C56BL/6 mice ( Supplementary Fig. 4a ). At areas around the BMMSC implants, CD4 + T cells produced IFN-γ and TNF-α, and CD11b + macrophages produced only TNF-α ( Supplementary  Fig. 4b ). In contrast, injection of an antibody that neutralizes IFN-γ (150 or 300 µg) and an antibody that neutralizes TNF-α (300 µg) partially rescued BMMSC-mediated bone formation in C57BL/6 mice ( Fig. 1g,h ). Injection of a combination of antibodies that neutralize IFN-γ and TNF-α at 300 µg significantly improved BMMSC-mediated bone formation (Fig. 1g,h ). These data confirm that both IFN-γ and TNF-α have key roles in governing BMMSC-based bone formation.
T reg cells have been reported to inhibit T cell activation and reduce IFN-γ and TNF-α production [16] [17] [18] [19] . Thus, we infused 1 × 10 6 T reg cells into C57BL/6 mice either 2 d or 7 d before BMMSC implantation and found a substantial amount of bone formation in the mice that were infused at 2 d before BMMSC implantation as compared to mice with untreated BMMSC implants (Fig. 2a,b) . Infusion with T reg cells at 7 d before BMMSC implantation did not improve bone formation in BMMSC implants (Fig. 2a,b) . To examine the protective role of T reg cells in BMMSC-based bone formation, we measured the cytokine concentrations in C57BL/6 mice treated with T reg cells. We observed that infusion of T reg cells reduced the concentrations of IFN-γ and TNF-α but not IL-4 and IL-10 ( Fig. 2c) in BMMSC implants. Subcutaneous implantation of BMMSCs did not affect the concentration of T reg cells in spleen (Fig. 2d) . Systemic infusion of T reg cells and BMMSCs elevated the concentration of T reg cells in spleen, which then were reduced to the control concentration 14 d after infusion (Fig. 2e,f ) . Infusion of 1 × 10 6 and 2 × 10 6 T reg cells showed a more significant elevation of T reg cells in spleen than infusion of 0.1 × 10 6 or 0.5 × 10 6 T reg cells (Fig. 2g) . Accordingly, infusion of 1 × 10 6 and 2 × 10 6 T reg cells, but not 0.1 × 10 6 or 0.5 × 10 6 T reg cells, was able to improve BMMSC-mediated bone formation in C57BL/6 mice (Fig. 2h,i) . These data collectively suggest that inhibition of IFN-γ and TNF-α improves BMMSC-based bone regeneration.
IFN-g inhibits the osteogenesis of BMMSCs
When we infused Ifng −/− T cells into nude mice, they did not block BMMSC-mediated bone formation ( Supplementary Fig. 5a-c) .
Further analysis showed that in vitro treatment with IFN-γ (200 ng ml −1 ), but not IL-6 (200 ng ml −1 ) or IL-17A (200 ng ml −1 ), inhibited osteogenic differentiation of BMMSCs compared to untreated BMMSCs (Fig. 3a) . IL-4 treatment (200 ng ml −1 ) served as a control that showed the inhibition of BMMSC osteogenic differentiation in vitro 20 (Fig. 3a) . Notably, treatment with 50 ng ml −1 of IFN-γ had no inhibitory effect on the osteogenic differentiation of BMMSCs (Fig. 3b) . The dose-dependent osteogenic inhibition caused by IFN-γ was associated with upregulated expression of Smad6, a negative regulator of osteogenic differentiation, and downregulated expression of the osteogenic genes encoding Runx2, osteocalcin (OCN) and alkaline phosphatase (ALP) in the mice treated with 200 ng ml −1 of IFN-γ, an effect that we did not observe in BMMSCs treated with 50 ng ml −1 of IFN-γ (Fig. 3c) . Furthermore, we found that IFN-γ treatment did not suppress osteogenic differentiation or alter the expression of Smad6 and Runx2 in Fas −/− BMMSCs (Fig. 3d ) or in BMMSCs with siRNA knockdown of Fas (Fig. 3e) .
IFN-g synergistically enhances TNF-a-induced BMMSC apoptosis
When we cultured BMMSCs with IFN-γ, TNF-α, IL-4, IL-6, IL-17A or TGF-β, only TNF-α significantly induced cell death in a dosedependent manner (Fig. 4a) . To determine the effect of IFN-γ on TNF-α-treated BMMSCs, we added 50 ng ml −1 of IFN-γ to BMMSCs that were treated with different doses of TNF-α (ranging from 1 to 200 ng ml −1 ; Fig. 4b) . Treatment with IFN-γ significantly enhanced BMMSC apoptosis when the TNF-α concentration reached at least 50 ng ml −1 ( Fig. 4b and Supplementary Fig. 5d,e) . To further confirm the synergistic effects of TNF-α and IFN-γ on the induction of BMMSC apoptosis, we added 50 ng ml −1 of TNF-α to BMMSCs that were treated with 1-200 ng ml −1 of IFN-γ (Fig. 4c) . The amount of BMMSC apoptosis was correlated with IFN-γ concentration at doses of 1-50 ng ml −1 . When IFN-γ concentration reached at least 100 ng ml −1 we observed complete BMMSC apoptosis (Fig. 4c) . In addition, we used immunocytostaining with annexin V to confirm that 50 ng ml −1 of IFN-γ enhanced BMMSC apoptosis mediated by 20 ng ml −1 of TNF-α (Fig. 4d) . Next, we verified the IFN-γ synergic effect on TNF-α-induced BMMSC apoptosis using an in vivo subcutaneous GFP + BMMSC implantation model 21, 22 . Thirty days after implantation, GFP + BMMSCs that were implanted with 50 ng ml −1 of TNF-α showed a significant reduction in the number of surviving cells compared to BMMSCs from the untreated group (Fig. 4e) . Combination treatment with 200 ng ml −1 of IFN-γ and 50 ng ml −1 of TNF-α led to no survival of GFP + BMMSCs in the implants (Fig. 4e) . These data indicate that IFN-γ is capable of synergistically enhancing TNF-α-induced BMMSC apoptosis.
We next found that IFN-γ treatment upregulated Fas expression in BMMSCs without activating caspase 3 and caspase 8 ( Fig. 4f and  Supplementary Fig. 5f ). After the addition of 20 ng ml −1 of TNF-α, a concentration that is unable to induce marked BMMSC apoptosis, to BMMSCs treated with 50 ng ml −1 of IFN-γ, we found that caspase 3 and caspase 8 were activated ( Fig. 4f and Supplementary Fig. 6a ) and that there was significant BMMSC apoptosis ( Fig. 4g,h) . However, treatment with a combination of 20 ng ml −1 of TNF-α and 50 ng ml −1 of IFN-γ did not activate caspase 3 and caspase 8 in Fas −/− BMMSCs (Fig. 4f) . We then used siRNA to knock down Fas expression in BMMSCs and found that activated caspase 8 and caspase 3 were partially blocked in BMMSCs treated with IFN-γ and TNF-α (Fig. 4g) , and we saw a significant reduction in the number of apoptotic BMMSCs (Fig. 4h) . These data suggest that Fas signaling is required for the IFN-γ synergistic effect on TNF-α-induced BMMSC apoptosis.
The next question we asked was how Fas apoptotic signaling is activated in BMMSCs treated with IFN-γ or TNF-α. We found that knockdown of FasL using siRNA in BMMSCs treated with IFN-γ or TNF-α was not able to reduce the number of apoptotic cells (Supplementary Fig. 6b ), which excluded FasL as a potential factor contributing to BMMSC apoptosis. We found that a combined treatment of IFN-γ and TNF-α induced Fas internalization and clustering. In the untreated control group, Fas was evenly distributed on the surface of the BMMSCs (Fig. 5a) . We treated BMMSCs with IFN-γ for 12 h and then added TNF-α; Fas showed marked clustering and internalization in the cytoplasm at 0.5-1 h after the combined treatment (Fig. 5a) . We observed Fas clustering in combination with cell shrinkage and cell membrane disruption at 2-4 h after treatment with TNF-α (Fig. 5a) . Blockage of Fas internalization with the endocytosis inhibitor latrunculin A partially rescued BMMSC apoptosis induced by IFN-γ or TNF-α in conjunction with an inhibition of cleaved caspase 3 and 8 (Fig. 5b) . Notably, after blocking the activities of caspase 8 or caspase 3 using specific inhibitors, BMMSCs treated with IFN-γ or TNF-α showed a significant reduction in the number of apoptotic cells (Fig. 5c) . Moreover, inhibition of pan-caspase, caspase 3 or caspase 8 was able to partially block Fas internalization (Fig. 5d) . These data suggest that Fas internalization and clustering contribute to synergistic BMMSC apoptosis through activation of caspase 8 or caspase 3 in the presence of IFN-γ and TNF-α.
We next investigated how a combination of IFN-γ and TNF-α resulted in Fas internalization and clustering in BMMSCs. First, we found that treatment with IFN-γ or TNF-α could not induce upregulation of TNFR1, tumor necrosis factor (ligand) superfamily, member 10 (TRAIL) or FasL proteins (Supplementary Fig. 6c ). We then found that treatment with IFN-γ (50 ng ml −1 ) and TNF-α (20 ng ml −1 ) in combination reduced the concentration of TNFR2 and that TNFR2's downstream signaling resulted in the phosphorylation of NF-κB, X-linked inhibitor of apoptosis (XIAP), CASP8 and FADD-like apoptosis regulator (FLIP) (Fig. 5e) , suggesting that IFN-γ and TNF-α combination treatment selectively inhibited the TNFR2-mediated anti-apoptotic effect. To confirm this hypothesis, we found that reduction of TNFR2, IκB kinase-like 2 (IKK), XIAP and FLIP by siRNA further activated caspase 8 and caspase 3 (Fig. 5f) . We confirmed the efficiency of TNFR2, IKK, XIAP and FLIP knockdown by their specific siRNAs using western blot analysis (Supplementary Fig. 6d) .
These findings collectively show that IFN-γ treatment activated Fas expression in BMMSCs and initiated a nonapoptotic pathway in which osteogenesis was inhibited by activation of Smad6 ( Supplementary  Fig. 7a) . Treatment of BMMSCs with IFN-γ and TNF-α together, however, was able to convert the nonapoptotic Fas signaling pathway to a death pathway (Supplementary Fig. 7b ).
T reg treatment improves BMMSC-based calvarial repair Because infusion of T reg cells inhibited the concentrations of TNF-α and IFN-γ (Fig. 2c) , we hypothesized that treatment with T reg cells might improve cell-based tissue engineering. To test this hypothesis, we generated critical-sized calvarial bone defects in wild-type mice (7 mm × 8 mm; Fig. 6a,b) . We observed very small amounts of bone formation in the untreated group at 12 weeks after surgery (Fig. 6b) . Implantation of BMMSCs and gelfoam at the site of the calvarial defect led to moderate bone regeneration but did not completely repair the defects (Fig. 6c) . However, infusion of T reg cells into recipients 2 d before BMMSC and gelfoam implantation resulted in complete repair of the defects (Fig. 6d) . A semiquantitative analysis showed the amount of calvarial bone regeneration in each group (Fig. 6e) . The regenerated bone structure in mice infused with T reg cells was identical to no-defect control and had complete suture regeneration (Fig. 6a,d ). These data imply that treatment with T reg cells improves BMMSC-mediated calvarial defect repair.
Aspirin treatment improves BMMSC-based calvarial repair Next, we investigated whether site-specific pharmacological treatments would improve BMMSC-based calvarial defect repair. Because aspirin has been reported to inhibit the function of TNF-α and IFN-γ 23 , we examined the effect of aspirin treatment on IFN-γ and TNF-α concentrations in BMMSC implants at 2-14 d after implantation. We found that aspirin treatment reduced the concentrations of IFN-γ and TNF-α without affecting IL-10 ( Supplementary Fig. 8) . When added to a BMMSC-activated T cell coculture system, 25, 50 and 100 µg ml −1 of aspirin significantly reduced the concentrations of IFN-γ and TNF-α (Supplementary Fig. 9 ). An immunohistochemical analysis confirmed the inhibitory effect of aspirin, shown by the reduction in the number of IFN-γ-and TNF-α-positive cells in the BMMSC implants (Fig. 6f) . To determine whether aspirin-mediated reduction of IFN-γ or TNF-α in BMMSC implants influenced the apoptosis of BMMSCs, we used a GFP + BMMSC implantation model, which showed a marked increase in the survival of BMMSCs in the aspirin-treated group at 4-30 d after implantation (Supplementary Fig. 10a) . Next, we studied the effect of aspirin on inhibition of exogenous IFN-γ and TNF-α and its effect on BMMSC-mediated bone formation. To determine the direct effect of aspirin on BMMSC osteogenic ability, we treated BMMSCs with 50 µg ml −1 of aspirin for 2 d and subcutaneously implanted them into nude mice using HA-TCP as a carrier. The aspirin pretreatment increased BMMSC-mediated bone formation compared to the untreated group (Supplementary Fig. 10b,c) . We then implanted BMMSCs that we treated with IFN-γ (200 ng) or TNF-α (200 ng) and observed significantly reduced bone formation (Fig. 1e,f and Supplementary Fig. 10d,e) . However, addition of aspirin (25-200 µg) to BMMSC implants restored the bone formation that was suppressed by IFN-γ or TNF-α (Supplementary Fig. 10f-h ). In addition, we found that implantation of BMMSCs with hydrogel and aspirin (25-200 µg) , together with BMMSCs with gelfoam and aspirin (100 µg), (Supplementary Fig. 11 ) resulted in a dose-dependent improvement of bone regeneration in the calvarial defect area compared to the control BMMSC group (Fig. 6g,h) . The structures of the regenerated tissues were analogous to normal calvarial tissues and the 100 µg and 200 µg treatment groups had complete suture regeneration (Fig. 6g,h ).
DISCUSSION
The clinical use of culture-expanded osteoprogenitor cells in conjunction with scaffolds has previously been reported for tissue engineering [24] [25] [26] . However, the main challenge of cell-based tissue regeneration is to form large quantities of tissue and high-quality tissue structures that match the body's functional needs 27, 28 . In this study, we developed a practical approach to improve BMMSC-based tissue engineering through suppression of IFN-γ and TNF-α using site-specific aspirin treatment.
In addition to IFN-γ-and TNF-α-induced BMMSC apoptosis, other immune cell-based regulatory mechanisms may also contribute to cell apoptosis in BMMSC implants. CD3-activated T lymphocytes are capable of inducing BMMSC apoptosis in a direct cell coculture system through the Fas-FasL pathway 15, 29 . In addition, T cells can induce BMMSC and osteoblast apoptosis through the CD40-CD40L pathway, as is observed in some models of bone-related diseases [30] [31] [32] [33] . Further studies are needed to determine whether donor BMMSC apoptosis attributes to the Fas-FasL and CD40-CD40L pathways.
It is not known how IFN-γ elevates Fas expression in BMMSCs and in other cells, such as those from osteosarcoma cell lines 34 . Notably, IFN-γ-induced Fas expression was associated with the IFN-γ-mediated blockage of osteogenic differentiation of BMMSCs by activating the Smad6 pathway. It is known that Smad6 inhibits osteogenic differentiation through bone morphogenetic protein (BMP) and Runx2 signaling 35, 36 .
However, a relatively high concentration of IFN-γ was required to inhibit the osteogenesis of the BMMSCs. Therefore, the inhibitory function of IFN-γ in BMMSC-mediated bone formation was probably a result of a synergistic effect with TNF-α, which resulted in enhanced BMMSC apoptosis by activation of a Fas-signaling-mediated death pathway. In this regard, IFN-γ treatment alone can upregulate Fas expression but does not induce BMMSC apoptosis, which might be attributed to the antiapoptotic function of TNFR2-associated NF-κB, XIAP and FLIP in this cascade 37, 38 . With the addition of TNF-α treatment, however, IFN-γ-induced nonapoptotic Fas signaling was converted to an apoptotic cascade as a result of the reduction of the anti-apoptotic factors NF-κB, XIAP and FLIP, as shown by Fas internalization and the activation of the death mediators caspase 3 and caspase 8.
Aspirin is a widely used nonsteroidal anti-inflammatory agent. It inhibits osteoclastogenesis and improves osteogenesis by affecting multiple biological pathways, for example, the inhibition of COX2, COX1 and PGE2 activity 15, 23, 39 . Epidemiological study has suggested that aspirin may have a moderate beneficial effect on bone mineral density in postmenopausal woman 15 . In studies using animal models, aspirin treatment improves bone formation and inhibits bone resorption in mice with ovariectomy-induced osteoporosis, which may associate with aspirin-induced upregulation of telomerase in BMMSCs 15, 40 . In this study, we showed that aspirin suppressed the concentrations of TNF-α and IFN-γ and reversed the proinflammatory cytokine-induced osteogenic deficiency of BMMSCs. We further used subcutaneous implantation and a model of calvarial bone defect repair to show that treatment with aspirin is an appropriate approach for improving BMMSC-based tissue regeneration through the suppression of IFN-γ and TNF-α. Although aspirin reduces TNF-α and IFN-γ production with improved BMMSC-based tissue regeneration, the therapeutic effect of aspirin in preclinical tests and clinical trials (for example, in improving fracture healing) may be the focus of future studies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
